Get started

GlycoMimetics, Inc.

No trades
See on Supercharts
Overview
News Ideas Financials Technicals Forecast

GLYC chart

Key stats

Market capitalization
98.522MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.64USD
Net income
−46.689MUSD
Revenue
75KUSD
Shares float
57.568M
Beta
1.89

About GlycoMimetics, Inc.

Sector
Health Technology
CEO
Harout Semerjian
Headquarters
Rockville
Website
glycomimetics.com
Employees (FY)
39
Founded
2003
ISIN
US38000Q1022
GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

Ideas

5 Hot Biotechs to Hold Over The WeekendMy Post-FDA Over-The-Weekend Watchlist: $GLYC $ONCT $ONCY $PIRS $AGEN All of these biotechs have phase one cancer treatment clinical-trial data releases this weekend. Based on my research, these are the ones that I think are most likely to release good data. Since they are all in phase one, it is
Long
by CobraTrader13
2
$GLYC Releases Trial Data For Cancer Treatment On The 10thFundamental Analysis: GlycoMimetics, Inc. is a clinical-stage biotechnology company that focuses on developing glycomimetics that inhibit disease-related functions of carbohydrates. They are currently developing a treatment for hormone receptor-positive metastatic breast cancer . The drug, GMI-13
Long
by Investor4321
GLYC look for the 26 break here. Biotech with bullish momentum Buy the Dips here. Strong momentum and will break 26. Data release on their earnings date in early March provides a great entry opportunity. Would NOT be surprised to see this bought out either. $30 price target on a swing/ $50 by EOY
Long
by THST
WORKED OFF THE FIRST LEGTHIS BIOTECH HAD A MONSTER MOVE FROM 5 TO 17 BEFORE COMING BACK TO EARTH. IT HAS SOME HIGH OCTANE PARTNERS LIKE PFIZER AND IS IN SEVERAL CLINICAL TRIALS. VOLUME DECLINED ON THE SELLOFF AND THE STOCK HAS BEEN RIDING THE 50 DAY m.a.AND JUST CLOSED ABOVE THE 13 DAY. THE OPTIONS HAVE ZERO OPEN INTERE
Long
by GreatWizeOz

See all ideas 

News Flow

Keep readingKeep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Financials

Performance
Revenue to profit conversion
Earnings
‪0‬

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
TradeStation
TradeStation
Featured
Stocks, Crypto, Futures
4.4Very Good
Learn more
Interactive Brokers
Interactive Brokers
Stocks, Futures, Bonds
4.4Very Good
Learn more

See all brokers